Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;14(6):536-542.
doi: 10.1007/s11897-017-0365-5.

Pharmacogenomics of the Natriuretic Peptide System in Heart Failure

Ahmed Abuzaanona  1 , David Lanfear  2
Affiliations
Review

Pharmacogenomics of the Natriuretic Peptide System in Heart Failure

Ahmed Abuzaanona et al. Curr Heart Fail Rep. 2017 Dec.

Abstract

Purpose of review: Heart failure (HF) continues to be a public health burden despite advances in therapy, and the natriuretic peptide (NP) system is clearly of critical importance in this setting, spawning valuable diagnostic and prognostic testing, such as B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), as well as current and future therapeutics, including recombinant natriuretic peptides (e.g., carperitide, nesiritide) and recently sacubitril, which inhibits the key clearance mechanism for NPs. This article intends to summarize the existing evidence for the role of NP system genetic variation on cardiovascular phenotypes relevant to HF with particular focus on the potential impact on pharmacologic therapies.

Recent findings: Several genes in NP system have been interrogated, in many cases genetic variation impacting protein quantity and function or related disease states. Recent data supports genetic variants potentially impacting pharmacokinetics or dynamics of medications targeting the pathway. Growing evidence indicates the importance of genetic variation to the functioning of the NP system and its pharmacologic manipulation.

Keywords: Genetics; Genomics; Guanylate cyclase; Heart failure; Natriuretic peptide receptors; Neutral endopeptidase; Personalized medicine; Polymorphism.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Ahmed Abuzaanona declares no conflicts of interest.

References

    1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135:e146–e603. - PMC - PubMed
    1. Ghani F, Wu A, Bijou R, et al. Circulating levels of B-type natriuretic peptide (BNP) are useful for diagnosis and are associated with severity of symptoms in chronic heart failure: preliminary data from a multicenter study with Bayer ADVIA Centaur (R) BNP assay. Clinical Chemistry. 2003;49:A67–A68.
    1. Tulevski II, Mulder BJ, van Veldhuisen DJ. Utility of a BNP as a marker for RV dysfunction in acute pulmonary embolism. J Am Coll Cardiol. 2002;39:2080. - PubMed
    1. Adlbrecht C, Neuhold S, Hulsmann M, et al. NT-proBNP as a means of triage for the risk of hospitalisation in primary care. Eur J Cardiovasc Prev Rehabil. 2011 - PubMed
    1. Gale CP, White JE, Hunter A, et al. Predicting mortality and hospital admission in patients with COPD: significance of NT pro-BNP, clinical and echocardiographic assessment. J Cardiovasc Med (Hagerstown) 2011;12:613–8. - PubMed